Referências Bibliográficas dos Artigos e Matérias Revista Newslab Edição 172

[vc_row][vc_column][vc_column_text]

ARTIGO I

BIOMARCADORES SÃO ÚTEIS PARA PREVER PROGNÓSTICO EM TRANSPLANTE DE CÉLULAS TRONCO HEMATOPOIÉTICAS (TCHT)?

• Anaissie E. Overview of infections following hematopoietic cell transplantation. UpToDate. April, 2012.
• Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586-4588.
• Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-Reactive protein is a predictor for outcomes after reduced-intensity allogeneicHematopoietic cell transplantation. Boil Blood Marrow Transplant. 2008; 14:1209-1216.
• Azarpira N, Ramzi M, Aghdaie M, Daraie M. Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. Exp Clin Transplant. 2009; 2:115-8.
• Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F,  Occhini D, Raiola AM, Mordini N, Berisso G, Bregante S, Dini G, Lombardi A, Van Lint MT, Brand R. Early predictors of transplant-related mortality  (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.  Bone Marrow Transplantation 1999; 24:653-659.
• Blijlevens NMA, Donnelly JP, Meis FGM, De Keizer MH, De Pauw BE. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 2000; 7(6):889-92.
• Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T, Markova M. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2008; 13(2):1-7.
• Charles PE, Tinel C, Barbar S. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit care 2009; 13:R38.
• Christ-Crain M, Jaccard-Stolz D, Bingisser R. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607.
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989; 86:668-72.
• Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000; 111(4):1093-102.
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-A H, Wingard JR. Clinical Practice Guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. CID. 2011: 52(4):e56-93.
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-54.
• Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115(20):4715-26.
• Hambach L, Eder M, Dammann E, Schrauder A, Sykora KW, Dieterich C. Diagnosis value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation . Haematologica. 2002; 87:643-51.
• Kanda J, Mizumoto C, Ichinohe T, Kawabata H, Saito T, Yamashita K, Kondo T, Takakura S, Ichiyama S, Uchiyama T, Ishikawa T. Pretransplant serum ferritin and C- reative protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010; 3:1-9.
• Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:195-204.
• Levin ASS, Dias MBGS, Oliveira MS, et al. Grupo e subcomissões de controle de infecção hospitalar do Hospital das Clínicas da FMUSP- Guia de Utilização de anti- Infecciosos e recomendações para prevenção de Infecções Hospitalares- Hospital das Clínicas da FMUSP-2009-2011; 52-7.
• Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med. 1980; 68(5): 643-8.
• Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41:997-1003.
• Mendes ET, Dulley F, Basso M, Batista MV, Coracin F, Guimarães T, Shikanai-Yasuda MA, Levin AS, Costa SF. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Intern J Infect Dis 2012a; 16:e424-e428.
• Mori Y, Miyawaki K, Kato K, Takenaka K, Iwasaki H, Harada N, Miyamoto T, Akashi K, Teshima T. Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. Inter Med 2011; 50:2149-2155.
• Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995; 86: 3979-86.
• Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J. Measurement of C-reactive protein in adults with febrile neutropenia after Hematopoietic cell transplantation. Bone Marrow Transplant 2004; 33:741-744.
• Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005; 74(4):297-303.
• Pihusch M, Pihusch R, Fraunberger P. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006; 76(2):93-101.
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72:101-11.
• Poliquin CM. Post-bone marrow transplant patient management. Yale J Biol Med. 1990; 63: 495-502.
• Remberger M, Mattsson J. C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. Int  J Hematol. 2010; 92:161-167.
• Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999; 18:283-5.
• Schots R, Kaufman L, van Riet I, Othman TB, De Waele M, Van Camp B, Demanet C. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17:1150-1156.
• Schots R, Van Riet I, Othman TB, Trullemans F, de Waele M, Van Camp B, Kaufman L. An early increase in serum levels of C-reactive protein is an Independent risk factor for the occurrence of major complications and 100- Day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplantation 2002; 30:441-446.
• Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-217. Erratum in: Clin Infect Dis. 2005; 40(9):1386-8.
• Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective randomized, double-blind study. J Infect Dis 1995; 171:1545.
• Sorely JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am. 1997; 11:459-77.
• Sorror ML, Maris MB, Storb R, Baron F, Sandmeier BM, Maloney DG. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106(8):2912-9.
• Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy. 2000; 46: 77-85.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

ARTIGO II

INCIDÊNCIAS DE INFECÇÕES POR ASPERGILLUS SP NO BRASIL

• AL-SHEIKH, H. M. Detecção LAMP-PCR de espécies de Aspergillus ocratoxigênicas coletadas a partir de grão de amendoim. Genética e Pesquisa Molecular, v.14, n.1, p. 634-644, jan. 2015.
• ALVEZ GRT, MARCHIORI E, Irion K, et al. Sinal do halo: achados de TCAR em 85 pacientes. J Bras Pneumol. 2016; 42:435–9.
• AZANZA JR, SÁDABA B, GÓMEZ-GUÍU A. Farmacologia de los antifúngicos en el tratamiento de la aspergilosis. Rev Iberoam Micol 2014; 31(4): 255–261. doi: 10.1016/j.riam. 2014.05.001.
• BADIE P, ALBORZI A, KARIMI M, POURABBAS B, HADDADI P, MARDANEH J, MOIENI M. Diagnostic potential of nested PCR, galactomannan EIA, and Beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries. 2012; 6(4): 352-7.
• BANDE, Y.M.; ADAM, N, M., AZNI, Y., JAMAREI, O. Moisture-dependente física e compressão de melão amargo (Citrullus lanatus colocynthis) sementes. International Journal de Pesquisa Agropecuária, V.7, p.243-254, 2012.
• BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). RDC7, de 18 de fevereiro de 2011. Dispõe sobre limites Maximos tolerados para micotoxinas em alimentos. Diário Oficial da União, Brasília. 18 fev. 2011. Disponível em <http://portal.anvisa.gov.br/wps/wcm/connect/bc17db804f45fe2cbd41fdd785749fbd/Resolu%C3%A7%C3%A3o+0-2011-CGALI.pdf?MOD+AJPERES>. Acesso em Set/2014.
• CABRAL GALEANO E, RUIZ-CAMPS I, LEN-ABAD O, et al. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. Enferm Infecc Microbiol Clin, 2015; 33(5): 298–302. doi: 10.1016/j.eimc.2014.09.005.
• CARDOSO FILHO, F. C. et al. Ocorrência de Aspergillus spp., Penicillium spp. e aflatoxinas em amostras de farinha de milho utilizadas no consumo humano, Piauí, Brasil. Arq. Inst. Biol., São Paulo, v. 78, n. 3, p. 443-447, jul./set., 2011.
• CARVALHO, L. I. C. Aspergillus e Aspegilose – Desafios no combate da doença. 2013. 43 f. Dissertação (Mestrado Integrado em Ciências Farmacêuticas) – Universidade Fernando Pessoa, Porto, 2013.
• DENNING DW, CARAMEL J, BEIGE MAN C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir Journal 2015; 47(1): 45–68. doi: 10.1183/13993003.00583-2015.
• DINIZ, S.P.S.S. Mycotoxins – Biochemical Approach. Ed. Albatroz, Rio de Janeiro, 2015, 186p.
• GIACOMAZZI, J. et al. The burden of serious human fungal infections in Brazil. Mycoses. v. 59, n. 3, p. 145-50. 2016.
• GONÇALEZ E, SILVA JL, REIS TA, NAKAI VK, FELÍCIO JD, CORRÊA B. Produção de aflatoxinas e ácido ciclopiazônico por cepas de Aspergillus flavus isoladas de amendoim. São Paulo: Arquivos do Instituto Biológico; 2013.
• JIANG, Z., WANG, Y., JIANG, Y., XU, Y. E MENG, B. Vertebral osteomyelitis and epidural abscess due to Aspergillus nidulans resulting in spinal cord compression: Case report and literature review.Journal of International Medical Research, 41(2), pp.502–510. 2013.
• JIANG, Z., WANG, Y., JIANG, Y.,Xu, Y. e MENG, B. (2013). Vertebral osteomyelitis and epidural abscess due to Aspergillus nidulans resulting in spinal cord compression:  Case  report  and  literature  review, Journal  of  International  Medical Research, 41(2), pp.502–510.
• KOUSHA, M., TADI, R. e SOUBANI, A.O.  (2011). Pulmonary aspergillosis: a clinical review, European Respiratory Review, 20(121), pp.156–174.
• LIAO, C.D., WONG, J. W., ZHANG, K., HAYWARD, D.G., LEE, N.S. e TRUCKSSES, M.W., 2013. Análise multi-micotoxina de grãos terminados. E produtos de nozes usando cromatografia líquida de alta eficiência-Espectrometria de massa de triplo-quadrupolo. Jornal de Agricultura e Food Chemistry 61: 4771-4782.
• LIU Z, WANG M, SUN W, et al. Up-regulation of Dectin-1 in airway epithelial cells promotes mice defense against invasive pulmonary aspergillosis. Int J Clin Exp Med 2015;8(10):17489-97.
• Maia, J. T. L. S; Sakata, R. A. P; Sabbag, S. P. Ocorrência de aflatoxinas em produtos alimentícios e o desenvolvimento de enfermidades. Enciclopédia Biosfera, vol. 7, n. 13, p. 1477-1498, 2011.
• MARTINEZ, Roberto et al . Primary aspergilloma and subacute invasive aspergillosis in two AIDS patients.Rev. Inst. Med. trop. S. Paulo, São Paulo, v. 51, n. 1, p. 49-52,  Feb.  2009.
• MARTÍN-RABADÁN P, GIJÓN P, FERNANDEZ RA, BALLESTEROS M, ANGUITAJ, BOUZA E. False-positive Aspergillus Antigenemia Due to Blood Product Conditioning Fluids. Clin Infect Dis. 2012; 55(4): 22-7.
• MINISTÉRIO DA SAÚDE. Secretaria de vigilância em saúde. Departamento de DST, AIDS e hepatite virais. Manual técnico para o dignóstico das infecções pelo HIV. Ministério da Saúde; Brasília, 2014.
• MONTEIRO, M. C., de  la  Cruz, M., Cantizani, J, Moreno, C.,Tormo, J.  R. MELLADO, E., De  Lucas, J.R ., Asensio, F.,Valiante, V.,Brakhage, A.  A.,Latgé,J.,Genilloud, O.  e Vicente  F.(2012). A New Approach to  Drug  Discovery:  High-Throughput  Screening  of  Microbial  Natural  Extracts  against  Aspergillus fumigatus Using Resazurin, Journal of Biomolecular Screening,17(4), pp.542–549.
• MUPUNGA, I.; LEBELO, S.L .; RHEEDER, J.P .; KATERERE, D. R. Ocorrência natural de aflatoxinas em amendoim e manteiga de amendoim de Bulawayo, no Zimbabwe. Journal of Food Protection, v. 77, n. 10, p.1814-1818, para fora. 2014.
• NISHIYAMA, Katia Hidemi et al . Traqueobronquite aguda causada por Aspergillus: relato de caso e achados de imagem.Radiol Bras, São Paulo, v. 47, n. 5, p. 317-319, Oct.  2014.
• OLIVEIRA JN, OLIVEIRA AV, MENEGHELLO ER. Análise Molecular de espécies de Aspergillus contaminantes de uvas vendidas no comércio de Maringá PR. Iniciação Científica CESUMAR. V. 15, n. 2, p. 157-163, Jul/Dez. 2013.
• PEREIRA, V. L.; FERNANDES, J. O.; CUNHA, S. C. – Mycotoxins in cereals and related foodstuffs: A review on occurrence and recent methods of analysis. Trends in Food Science and Technology. 36:2 (2014) 96-136.
• SAVH, ATALAY MA, DEMIR G, OZDEMIR MA, KOC AN. Diagnosi tempestiva di aspergillosi cerebrale effettuata con metodi differenti: caso clinico. Infezioni Med. 2013; 2:134-8.
• SELIM, K.M.; EL-HOFY, H.; KHALIL, R.H. O eficaz de três absorvente de micotoxinas para aliviar Aflatoxina B1-Toxicidade induzida em Oreochro MisNiloticus. Aquicultura Internacional, N.22, p.523-540, 2014.
• SOARES, C; ABRUNHOSA, L; VENÂNCIO A. Fungos produtores de micotoxinas. Microbiologia Portuguese Society for Microbiology Magazine, 2013. Disponível em: https://repositorium.sdum.uminho.pt/bitstream/1822/27316/3/Fungos%20produtores%20de% 20micotoxinas%20-%20Microbiologia.pdf. Acesso em 20. Ago.2018.
• TÃNASE AD, COLIBÃ A, MÃRCULESCU A, BERTEANU C, STREINU Cercel A, STOICA M, et al. Using the galactomannan antigen assay in the diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Rom J Morphol Embryol. 2012; 53(2): 379-82.
• TIBOLA, A.C.S.; FERNANDES, J.M.C.; GUARIENTI, E.M.; NICOLAU, M. Distribution of Fusarium mycotoxins in wheat  milling process.   Food Control. v. 53 p. 91-95, 2015.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

ARTIGO III

PROTEÍNA TAU E AS DOENÇAS NEURODEGENERATIVAS

• BAKOTA, L., Brandt, R. Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease. Drugs. n. 76, v. 3 págs. 301-13, 2016 doi: 10.1007/s40265-015-0529-0.
• BIGMAN, L.S., Levy, Y. Proteins: molecules defined by their trade-offs. Curr Opin Struct Biol. n. 60, págs. 50-56, 2020 doi: 10.1016/j.sbi.2019.11.005.
• Gouras GK, Olsson TT, Hansson O. β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics.  Jan n. 12, v. 1 págs.13-11, 2015 doi: 10.1007/s13311-014-0313-y.
• Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. n. 15, v.10, págs. 565-581, 2019 doi: 10.1038/s41582-019-0244-7.
• JOUANNE, M., Rault, S., Voisin-Chiret, A.S. Tau protein aggregation in Alzheimer’s disease: An attractive target for the development of novel therapeutic agents. Eur J Med Chem. n. 20, v. 139, págs. 153-167, 2017 doi: 10.1016/j.ejmech.2017.07.070.
• KO, P.J., Dixon, S.J. Protein palmitoylation and cancer. EMBO Rep. n. 19, v. 10, e46666, 2018 doi: 10.15252/embr.201846666.
• MAGALHÃES, L. Proteínas. Toda Matéria, 2020
• Mancinelli R, Carpino G, Petrungaro S, Mammola CL, Tomaipitinca L, Filippini A, Facchiano A, Ziparo E, Giampietri C. Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases. Oxid Med Cell Longev. n. 20, v. 17 e4629495, 2017doi: 10.1155/2017/4629495.
• MARTIN, L., Latypova, X., Wilson, C.M., Magnaudeix, A., Perrin, M.L., Yardin, C., Terro, F. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev. n. 12, v. 1, págs. 289-309, 2013 doi: 10.1016/j.arr.2012.06.003
• Martins, L.M Santos, J.R.S. Inibição do glicogênio sintase cinase 3 como Nova abordagem no controle da dor aguda e Crônica: análise dos mecanismos de ação. [Tese] Universidade Federal de Santa Catarina, 2013
• PANCSA, R., Schad, E., Tantos, A., Tompa, P. Emergent functions of proteins in non-stoichiometric supramolecular assemblies. Biochim Biophys Acta Proteins Proteom. n. 1867, v.10 págs. 970-979, 2019 doi: 10.1016/j.bbapap.2019.02.007.
• Paz, D.P. Bioquímica de proteínas: Proteína Tau. Passei direto, 2020
• PÎRŞCOVEANU, D.F.V, Pirici, I., Tudorică, V., Bălşeanu, T.A., Albu, V.C., Bondari, S., Bumbea, A.M., Pîrşcoveanu, M. Tau protein in neurodegenerative diseases – a review. Rom J Morphol Embryol. n. 58, v. 4, págs.1141-1150, 2017
• Rey, N.A. Rachel, A. Cukierman, S.D. Falco, A.D. Doença de alzheimer: hipóteses etiológicas e perspectivas de tratamento. Revista Química Nova.  n. 39 v. 1, 2016 doi: https://doi.org/10.5935/0100-4042.20150152
• RUSEK, M., Pluta, R., Ułamek-Kozioł, M., Czuczwar, S.J. Ketogenic Diet in Alzheimer’s Disease. Int J Mol Sci. Aug n. 9, v. 20 e3892, 2019 doi: 10.3390/ijms20163892.
• Soria Lopez JA, González HM, Léger GC. Alzheimer’s disease. Handb Clin Neurol. n. 167, págs. 231-255, 2019 doi: 10.1016/B978-0-12-804766-8.00013-3.
• Srivastava AK, Pittman JM, Zerweck J, Venkata BS, Moore PC, Sachleben JR, Meredith SC. β-Amyloid aggregation and heterogeneous nucleation. Protein Sci. n. 28, v. 9, págs.1567-1581, 2019 doi: 10.1002/pro.3674.
• Yang K, Chen Z, Gao J, Shi W, Li L, Jiang S, Hu H, Liu Z, Xu D, Wu L. The Key Roles of GSK-3β in Regulating Mitochondrial Activity. Cell Physiol Biochem. n. 44, v.4, págs.1445-1459, 2017 doi: 10.1159/000485580.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Análises Clínicas

HIPERCALCEMIA ASSOCIADA AO CÂNCER

• Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med. 2022 Apr 14;386(15):1443-1451. doi: 10.1056/NEJMcp2113128. PMID: 35417639.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Citometria de Fluxo

O QUE É CITOMETRIA DE FLUXO ESPECTRAL?

• Bonilla, D. L. Bonilla, Reinin,G and Chua, E. Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy, from Front. Biosci., 29 January 2021 | https://doi.org/10.3389/fmolb.2020.612801

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

LabNews

A IMPORTÂNCIA DA VITAMINA D E SUA DOSAGEM.

• Ali Daneshkhah, Vasundhara Agrawal, Adam Eshein, Hariharan Subramanian, Hemant K. Roy, Vadim Backman. The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. medRxiv 2020.04.08.20058578; doi: https://doi.org/10.1101/2020.04.08.2005857
• Castro, Luiz Claudio Gonçalves de O. sistema endocrinológico vitamina D. Arquivos Brasileiros de Endocrinologia & Metabologia [online]. 2011, v. 55, n. 8 [Acessado 17 Junho 2022], pp. 566-575. Disponível em: <https://doi.org/10.1590/S0004-27302011000800010>. Epub 03 Jan 2012. ISSN 1677-9487. https://doi.org/10.1590/S0004-27302011000800010.
• Ceolin, G., Mano, G., Hames, N. S., Antunes, L., Brietzke, E., Rieger, D. K., & Moreira, J. D. (2021). Vitamin D, Depressive Symptoms, and Covid-19 Pandemic. Frontiers in neuroscience, 15, 670879. https://doi.org/10.3389/fnins.2021.670879
• Pereira, M Damascena, A D Azevedo, L M G Oliveira, T A Santana, J M. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Food Science and Nutrition [Internet]. 4 de novembro de 2020 [citado 7 de janeiro de 2021]; Disponível em: https://doi.org/10.1080/10408398.2020.1841090
• Schuch, Natielen Jacques, Garcia, Vivian Cristina e Martini, Ligia Araújo.Vitamina D e doenças endocrinometabólicas. Arquivos Brasileiros de Endocrinologia & Metabologia [online]. 2009, v. 53, n. 5 [Acessado 9 Fevereiro 2022] , pp. 625-633. Disponível em: <https://doi.org/10.1590/S0004-27302009000500015>. Epub 11 Set 2009. ISSN 1677-9487. https://doi.org/10.1590/S0004-27302009000500015.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Medicina Genômica

SEQUENCIAMENTO DE TERCEIRA GERAÇÃO:

• XIAO, T; ZHOU, W. The third generation sequencing: the advanced approach to genetic diseases. Translational Pediatry, v. 9, p. 163-173, 2020.
• RHOADS, A; AU, K.F. PacBio Sequencing and Its Applications. Genomics, Proteomics & Bioinformatics, v. 13, p. 278-289, 2015.
• COCCARO, N et al. Next-Generation Sequencing in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, v. 20, 2019.
• BLEIDORN, C. Third generation sequencing: technology and its potential impact on evolutionary biodiversity research. Systematics and Biodiversity, v. 14, p. 1-8, 2016.
• SCHADT, E;  TURNER, S; KASARSKIS, A. A window into third generation sequencing, Human Molecular Genetics, v. 19, p. 227-240, 2010.
• LI, Y et al. Recovery of human gut microbiota genomes with third-generation sequencing. Cell & Death Disease, v. 12, 2020.
• HEATHER, J; CHAIN, B. The sequence of sequencers: The history of sequencing DNA. Genomics, v. 107, p. 1-8, 2016.
• GIANI, A. M. Long walk to genomics: History and current approaches to genome sequencing and assembly. Computational and Structural Biotechnology Journal, v. 18, p. 9-19, 2020.
• ATHANASOPOULOU, K et al.. Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics. Life, v. 12,  2022
• KCHOUK, M.; GIBRAT, J.; ELLOUMI, M. Generations of Sequencing Technologies: From First to Next Generation. Biology and Medicine, v. 9, 2017.
• KUMAR, K.; COWLEY, M; DAVIS, R. Next-Generation Sequencing and Emerging Technologies. Seminars in Thrombosis and Hemostasis, v. 45, p. 661-673, 2019.
• PAYNE, A. et al. In situ genome sequencing resolves DNA sequence and structure in intact biological samples. Science, v. 371, 2020.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Minuto Laboratório

AUDITORIA INTERNA: DO AUDITOR AO AUDITADO – O QUE ESPERAR?

• Richard F. Chambers, presidente e CEO do Global Institute of Internal Auditors.
• AUDITORIA: UMA ABORDAGEM HISTÓRICA E ATUAL -Rev. adm. saúde; 12(47): 71-78, abr.jun. 2010

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Neurociência em foco

ESTUDO DEFENDE QUE ESCLEROSE MÚLTIPLA É UMA COMPLICAÇÃO RARA DE INFECÇÃO POR VÍRUS

• https://www.neurodiem.com.br/talk/epstein-barr-virus-leading-cause-of-ms-IcluFPUWgIwPcEGdivYuc

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Qualidade no laboratório

O IMPACTO DO TEMPO DE SEPARAÇÃO DAS AMOSTRAS BIOLÓGICAS NOS EXAMES LABORATORIAIS.

• Lundberg GD. How clinicians should use the diagnostic laboratory in a changing medical world. Clinica Chimica Acta. 1999;280(1-2):3-11.
• ENEAS. Estudio nacional sobre los efectos adversos ligados a la hospitalización. ENEAS 2005. Informe. Febrero 2006.
• Plebani M, Carraro P. Mistakes in a stat laboratory: types and frequency. Clin Chem. 1997;43(8 Pt 1):1348-51.
• Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44(6):750-9.
• Guder WG, Narayanan S, Wisser HT, Zawta B. Samples: from the patient to the laboratory. The impact of preanalytical variables on the quality of laboratory results. 3. ed. Darmstadt: Git Verlag GMBH; 2003.
• Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry. 2. ed. Philadelphia: WB Saunders; 1994.
• NCCLS/CLSI. Procedure for the handling and processing of blood specimens; approved Guideline 3. ed. Wayne: CLSI; 2004. 24(38).
• Tanner M, Kent N, Smith B, Fletcher S, Lewer M. Stability of common biochemical analytes in serum gel tubes subjected to various storage temperatures and times pre-centrifugation. Annals of Clinical Biochemistry. 2008;45:375-9.
• Zhang DJ, Elswick RK, Miller WG, Bailey JL. Effect of serum-clot contact time on clinical chemistry laboratory results. Clinical Chemistry. 1998;44:6:1325-33.

[/vc_column_text][vc_separator color=”black”][/vc_column][/vc_row]